Full Press Release Details
EIP Pharma Announces Presentation of Positive Clinical Trial Results with Neflamapimod at the 13th Clinical Trials in Alzheimer's Disease (CTAD) Meeting.
CRVO
EIP Pharma Announces Presentation of Positive Clinical Trial Results with Neflamapimod at the 13th Clinical Trials in Alzheimer's Disease (CTAD) Meeting
Key Takeaway: EIP Pharma Announces Presentation of Positive Clinical Trial Results with Neflamapimod at the 13th Clinical Trials in Alzheimer's Disease (CTAD) Meeting
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
6.8%
average across 6 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
Neflamapimod
Phase 2 · Moderate to Severe Acute Ischaemic Stroke